FC Rad Onc (SA) Part II - Paper 3. October 2020

Paper III

		Questions 1 & 2 (50%)													Question 3 & 4 (50											
		UROLOGY						LUNG			HAEM				CNS						SKIN			Paediatric ra		
		Bladder	Kidney	Prostate	Penis	Testis	Other	Lung -NSCLC	Lung - SCLC	Other	Hodgkins lymphoma	Non-Hodgkin's lymphoma	Multiple Myeloma	Other	Meningioma	Glioma	Pituitary adenoma	Spinal cord tumours	Benign brain tumours	Other	BCC/SCC	Melanoma	Other	Wilm's tumour	Brain tumours	Rhabdomyosarcoma
PRE-TREATMENT (30%)	Prevention																									
	Screening																									
	Aetiology																									
	Diagnosis																									
	Staging																									
	Pathology																									
TREATMENT (60%)	General																									
	Radiotherapy																									
	Chemotherapy																									
	Biological therapy																									
	Side effects of therapy																									
(5%)	Prognosis																									

POST-TREATMENT	Follow-up																											
	Late effects																											
	Palliative Care																											
MISCELLANEOUS (5%)	Emergencies																											
	Other																											

Note:The mark allocation in percentages in column 1 is an approximate guide only.

*** Only overview knowledge of surgery and systemic therapies is required. Detailed knowledge of radiotherapy is required**

**** Only benign diseases commonly treated with radiotherapy will be asked**

%)

ıdiotherapy*			Misc.				
Neuroblastoma	Other	Special considerations	Adolescents and young adults	Sarcomas (bone and soft tissue)	Thyroid cancer	Unknown primary	Benign diseases**